CDK Inhibitors

CDK1

CDK2

CDK3

CDK4

CDK5

CDK6

CDK7

CDK8

CDK9

CDK11

CDK12

CDK13

CDK14

CDK16

CDK19

CDC

CLK

Pho85

CDK Degraders, Inhibitors, Antagonists & Activators

Product Name	CDK1	CDK2	CDK3	CDK4	CDK5	CDK6	CDK7	CDK8	CDK9	CDK11	CDK12	CDK13	CDK14	CDK16	CDK19	CDC	CLK	Pho85	Purity
Palbociclib				Cdk4/cyclin D3, IC₅₀: 9 nM Cdk4/cyclin D1, IC₅₀: 11 nM		Cdk6/cyclin D2, IC₅₀: 16 nM													99.94%
Abemaciclib	CDK1/cyclinB1, IC₅₀: 1627 nM	CDK2/cyclinE, IC₅₀: 504 nM		Cdk4/cyclin D1, IC₅₀: 2 nM	CDK5/p35, IC₅₀: 287 nM Cdk5/p25, IC₅₀: 355 nM	CDK6/cyclinD1, IC₅₀: 10 nM	CDK7/Mat1/cyclinH1, IC₅₀: 3910 nM		CDK9/cyclinT1, IC₅₀: 57 nM										99.97%
Ribociclib				CDK4, IC₅₀: 10 nM		CDK6, IC₅₀: 39 nM													99.94%
Ro-3306	CDK1, Ki: 20 nM CDK1/cyclinB1, Ki: 35 nM CDK1/cyclin A, Ki: 110 nM	CDK2/cyclinE, Ki: 340 nM																	98.68%
Dinaciclib	CDK1, IC₅₀: 3 nM	CDK2, IC₅₀: 1 nM			CDK5, IC₅₀: 1 nM				CDK9, IC₅₀: 4 nM										99.36%
PF 477736	CDK1, Ki: 9.9 μM																		99.21%
Flavopiridol	CDK1/Cyc B1, IC₅₀: 30 nM	CDK2/Cyc E, IC₅₀: 170 nM		CDK4/Cyc D1, IC₅₀: 100 nM															99.73%
GSK3326595				CDK4		CDK6													99.97%
Palbociclib monohydrochloride				Cdk4/cyclin D3, IC₅₀: 9 nM Cdk4/cyclin D1, IC₅₀: 11 nM		Cdk6/cyclin D2, IC₅₀: 16 nM													99.98%
(R)-Roscovitine	cdc2/cyclin B, IC₅₀: 0.65 μM	cdk2/cyclin A, IC₅₀: 0.7 μM Cdk2/cyclin E2, IC₅₀: 0.7 μM			CDK5/p35, IC₅₀: 0.16 μM														99.84%
THZ1							CDK7, IC₅₀: 3.2 nM												99.84%
Abemaciclib methanesulfonate	CDK1/cyclinB1, IC₅₀: 1627 nM	CDK2/cyclinE, IC₅₀: 504 nM		Cdk4/cyclin D1, IC₅₀: 2 nM	Cdk5/p25, IC₅₀: 355 nM CDK5/p35, IC₅₀: 287 nM	CDK6/cyclinD1, IC₅₀: 10 nM	CDK7/Mat1/cyclinH1, IC₅₀: 3910 nM		CDK9/cyclinT1, IC₅₀: 57 nM										99.95%
AZD4573									CDK9, IC₅₀: 4 nM										99.98%
THZ531							CDK7, IC₅₀: 8.5 μM		CDK9, IC₅₀: 10.5 μM		CDK12, IC₅₀: 158 nM	CDK13, IC₅₀: 69 nM							99.86%
Palbociclib isethionate				Cdk4/cyclin D3, IC₅₀: 9 nM Cdk4/cyclin D1, IC₅₀: 11 nM		Cdk6/cyclin D2, IC₅₀: 16 nM													99.99%
Kenpaullone	Cdk1/cyclin B, IC₅₀: 0.4 μM	cdk2/cyclin A, IC₅₀: 0.68 μM CDK2/cyclinE, IC₅₀: 7.5 μM			Cdk5/p25, IC₅₀: 0.85 μM														98.20%
Atirmociclib				Cdk4/cyclin D1, Ki: 0.6 nM		cdk6/cyclin D3, Ki: 13.9 nM													99.87%
SR-4835											CDK12, IC₅₀: 99 nM CDK12, Kd: 98 nM	CDK13, Kd: 4.9 nM							99.73%
Toyocamycin		CDK2/cyclinA, IC₅₀: 0.67 μM		Cdk4/cyclin D3, IC₅₀: 15 μM		cdk6/cyclin D3, IC₅₀: >10 μM	CDK7/Mat1/cyclinH1, IC₅₀: 2.8 μM		CDK9/cyclinT1, IC₅₀: 79 nM										99.78%
SY-5609		CDK2, Ki: 2600 nM					CDK7, Kd: 0.065 nM		CDK9, Ki: 960 nM		CDK12, Ki: 870 nM								99.66%
SNS-032	CDK1, IC₅₀: 480 nM	CDK2, IC₅₀: 38 nM		CDK4, IC₅₀: 925 nM			CDK7, IC₅₀: 62 nM		CDK9, IC₅₀: 4 nM										99.54%
Wogonin								CDK8											99.92%
GSK 3 Inhibitor IX	Cdk1/cyclin B, IC₅₀: 320 nM	cdk2/cyclin A, IC₅₀: 300 nM		Cdk4/cyclin D1, IC₅₀: 10 μM	CDK5/p35, IC₅₀: 80 nM														99.74%
Amantadine		CDK2																	99.90%
OTS964 hydrochloride										CDK11B, Kd: 40 nM									99.74%
NVP-2									CDK9, IC₅₀: 0.5 nM										99.60%
Palbociclib hydrochloride				Cdk4/cyclin D3, IC₅₀: 9 nM Cdk4/cyclin D1, IC₅₀: 11 nM		Cdk6/cyclin D2, IC₅₀: 16 nM													99.93%
Samuraciclib hydrochloride	CDK1, IC₅₀: 1.8 μM	CDK2, IC₅₀: 578 nM		CDK4, IC₅₀: 49 μM	CDK5, IC₅₀: 9.4 μM	CDK6, IC₅₀: 34 μM	CDK7, IC₅₀: 41 nM		CDK9, IC₅₀: 1.2 μM										99.98%
Simurosertib																Cdc7, IC₅₀: <0.3 nM			99.94%
JNJ-7706621	Cdk1/cyclin B, IC₅₀: 9 nM	CDK2/cyclinE, IC₅₀: 3 nM cdk2/cyclin A, IC₅₀: 4 nM	CDK3/Cyclin E, IC₅₀: 58 nM	Cdk4/cyclin D1, IC₅₀: 253 nM		CDK6/cyclinD1, IC₅₀: 175 nM													99.91%
KB-0742 dihydrochloride									CDK9/cyclinT1, IC₅₀: 6 nM										99.24%
AT7519	Cdk1/cyclin B, IC₅₀: 210 nM	cdk2/cyclin A, IC₅₀: 47 nM		Cdk4/cyclin D1, IC₅₀: 100 nM	CDK5/p35, IC₅₀: 13 nM	cdk6/cyclin D3, IC₅₀: 170 nM	CDK7/Cyclin H/MAT1, IC₅₀: 2400 nM		CDK9/Cyclin T, IC₅₀: 10 nM										99.76%
hSMG-1 inhibitor 11j	CDK1, IC₅₀: 32 μM	CDK2, IC₅₀: 7.1 μM																	99.82%
Tagtociclib hydrate		CDK2/cyclin E1, Ki: 1.16 nM																	99.95%
(+)-Enitociclib									CDK9/CycT1, IC₅₀: 3 nM										99.66%
MBQ-167																Cdc42, IC₅₀: 78 nM			99.86%
CPS2		CDK2, IC₅₀: 24 nM																	99.33%
Fadraciclib		CDK2							CDK9										99.78%
BSJ-4-116											CDK12, IC₅₀: 6 nM								98.73%
BI-1347								CDK8, IC₅₀: 1.1 nM											99.84%
TG003																	CLK1, IC₅₀: 20 nM CLK2, IC₅₀: 200 nM CLK4, IC₅₀: 15 nM		99.57%
Ribociclib hydrochloride				CDK4, IC₅₀: 10 nM		CDK6, IC₅₀: 39 nM													99.95%
Flavopiridol Hydrochloride	CDK1/Cyc B1, IC₅₀: 30 nM	CDK2/Cyc E, IC₅₀: 170 nM		CDK4/Cyc D1, IC₅₀: 100 nM															99.73%
AZD-5438	cdk1-cyclin B1, IC₅₀: 16 nM	cdk2-cyclin E, IC₅₀: 6 nM cdk2-cyclin A, IC₅₀: 45 nM		cdk4-cyclin D1, IC₅₀: 449 nM	cdk5-p25, IC₅₀: 14 nM	cdk6-cyclin D3, IC₅₀: 21 nM	cdk7-cyclin H, IC₅₀: 821 nM		cdk9-cyclin T, IC₅₀: 20 nM										99.85%
AS2863619								CDK8, IC₅₀: 0.61 nM							CDK19, IC₅₀: 4.28 nM				99.94%
TL12-186		cdk2/cyclin A, IC₅₀: 73 nM							CDK9/cyclinT1, IC₅₀: 55 nM										99.63%
Ribociclib succinate				CDK4, IC₅₀: 10 nM		CDK6, IC₅₀: 39 nM													99.93%
YKL-5-124		CDK2, IC₅₀: 1300 nM					CDK7, IC₅₀: 53.5 nM CDK7/Mat1/CycH, IC₅₀: 9.7 nM		CDK9, IC₅₀: 3020 nM										98.79%
CVT-313	Cdk1/cyclin B, IC₅₀: 4.2 μM	cdk2/cyclin A, IC₅₀: 0.5 μM		Cdk4/cyclin D1, IC₅₀: 215 μM															99.90%
NG 52	cdc2-cyclin B, IC₅₀: 0.34 μM				Pho85p, IC₅₀: 2 nM														99.97%
MSC2530818								CDK8, IC₅₀: 2.6 nM											99.62%
CLK-IN-T3																	CLK1, IC₅₀: 0.67 nM CLK2, IC₅₀: 15 nM CLK3, IC₅₀: 110 nM		98.63%
SEL120-34A monohydrochloride								CDK8/CycC, IC₅₀: 4.4 nM	CDK9/cycT, IC₅₀: 1070 nM						CDK19/CycC, IC₅₀: 10.4 nM				99.29%
(R)-CR8	Cdk1/cyclin B, IC₅₀: 0.09 μM	cdk2/cyclin A, IC₅₀: 0.072 μM CDK2/cyclinE, IC₅₀: 0.041 μM			Cdk5/p25, IC₅₀: 0.11 μM		CDK7/cyclin H, IC₅₀: 1.1 μM		CDK9/Cyclin T, IC₅₀: 0.18 μM										99.61%
(E/Z)-Zotiraciclib		CDK2, IC₅₀: 13 nM																	99.96%
BSJ-03-123						CDK6													98.12%
XL413 monohydrochloride																Cdc7, IC₅₀: 3.4 nM			99.72%
CGP60474	CDK1-Cyclin B, IC₅₀: 26 nM	CDK2/cyclinE, IC₅₀: 3 nM cdk2/cyclin A, IC₅₀: 4 nM		CDK4/cyclin D, IC₅₀: 216 nM	Cdk5/p25, IC₅₀: 10 nM		CDK7/cyclin H, IC₅₀: 200 nM		CDK9/cycT, IC₅₀: 13 nM										99.23%
Nimbolide				CDK4		CDK6													99.72%
hSMG-1 inhibitor 11e	CDK1, IC₅₀: 32 μM	CDK2, IC₅₀: 7.1 μM																	99.81%
CTX-712																	CLK2, IC₅₀: 1.4 nM		98.60%
Cucurbitacin E	cyclin B1/CDC2																		99.92%
BSJ-04-132				CDK4/D1, IC₅₀: 50.6 nM		CDK6/D1, IC₅₀: 30 nM													99.07%
AUZ 454		CDK2(C118L/A144C), Kd: 9.7 nM CDK2(A144C), Kd: 15.4 nM CDK2(C118L), Kd: 18.6 nM CDK2(WT), Kd: 50 nM CDK2(C118L/A144C-Cyclin B), Kd: 134.1 nM																	99.57%
Mevociclib							CDK7												99.27%
BTX-A51							CDK7, Kd: 1.3 nM		CDK9, Kd: 4 nM										98.58%
PROTAC CDK2/9 Degrader-1		CDK2, DC₅₀: 62 nM							CDK9, DC₅₀: 33 nM										99.85%
Ebvaciclib		CDK2, Ki: 0.09 nM		CDK4, Ki: 0.13 nM		CDK6, Ki: 0.16 nM													99.98%
Roniciclib	Cdk1/cyclin B, IC₅₀: 7 nM	CDK2/cyclinE, IC₅₀: 9 nM		CDK4/cyclin D, IC₅₀: 11 nM			CDK7/Cyclin H/MAT1, IC₅₀: 25 nM		CDK9/cyclinT1, IC₅₀: 5 nM										98.09%
CCT-251921								CDK8, IC₅₀: 2.3 nM							CDK19, IC₅₀: 2.6 nM				99.01%
FMF-04-159-2		CDK2, IC₅₀: 256 nM (in NanoBRET assay)											CDK14/Cyclin Y, IC₅₀: 39.6 nM (in NanoBRET assay)						99.48%
BSJ-03-204				CDK4/D1, IC₅₀: 26.9 nM		CDK6/D1, IC₅₀: 10.4 nM													99.76%
NU6300		CDK2
Purvalanol A	cdc2-cyclin B, IC₅₀: 4 nM	cdk2-cyclin E, IC₅₀: 35 nM cdk2-cyclin A, IC₅₀: 70 nM		cdk4-cyclin D1, IC₅₀: 850 nM	cdk5-p35, IC₅₀: 75 nM														98.30%
XY028-140				CDK4		CDK6													98.42%
Senexin A								CDK8, Kd: 0.83 μM CDK8, IC₅₀: 280 nM							CDK19, Kd: 0.31 μM				99.79%
LDC000067	cdk1-cyclin B1, IC₅₀: 5513 nM	cdk2-cyclin A, IC₅₀: 2441 nM		cdk4-cyclin D1, IC₅₀: 9242 nM					CDK9- Cyclin T1, IC₅₀: 44 nM										98.09%
THZ1 Hydrochloride							CDK7, IC₅₀: 3.2 nM												98.61%
R547	Cdk1/cyclin B, Ki: 2 nM Cdk1/cyclin B, IC₅₀: 0.2 nM	CDK2/cyclinE, Ki: 3 nM cdk2/cyclin A, IC₅₀: 0.1 nM CDK2/cyclinE, IC₅₀: 0.4 nM	CDK3/Cyclin E, IC₅₀: 0.8 nM	CDK4/cyclin D, Ki: 1 nM	CDK5/p35, IC₅₀: 0.1 nM	cdk6/cyclin D3, IC₅₀: 4 nM	CDK7/cyclin H, IC₅₀: 171 nM												99.57%
T025																	CLK1, Kd: 4.8 nM CLK2, Kd: 0.096 nM CLK3, Kd: 6.5 nM CLK4, Kd: 0.61 nM		99.64%
BMS-265246	CDK1/cycB, IC₅₀: 6 nM	CDK2/Cyc E, IC₅₀: 9 nM		CDK4/cycD, IC₅₀: 230 nM															98.92%
Asnuciclib	CDK1, IC₅₀: 8.17 nM CDK1, Ki: 4 nM	CDK2, IC₅₀: 3.27 nM CDK2, Ki: 3 nM		CDK4, IC₅₀: 8.18 nM		CDK6, IC₅₀: 37.68 nM	CDK7, IC₅₀: 134.26 nM CDK7, Ki: 91 nM		CDK9, IC₅₀: 5.78 nM CDK9, Ki: 4 nM										99.76%
PHA-767491 hydrochloride	CDK1, IC₅₀: 250 nM	CDK2, IC₅₀: 240 nM			CDK5, IC₅₀: 460 nM				CDK9, IC₅₀: 34 nM										99.49%
Amantadine hydrochloride		CDK2																	≥98.0%
Milciclib	cyclin B/CDK1, IC₅₀: 398 nM	cyclin A/CDK2, IC₅₀: 45 nM cyclin E/CDK2, IC₅₀: 363 nM		cyclin D1/CDK4, IC₅₀: 160 nM			cyclin H/CDK7, IC₅₀: 150 nM												99.90%
Abemaciclib metabolite M2				CDK4, IC₅₀: 1.2 nM		CDK6, IC₅₀: 1.3 nM													99.94%
(R)-CR8 trihydrochloride	CDK1/cyclinB1, IC₅₀: 0.09 μM	cdk2/cyclin A, IC₅₀: 0.072 μM CDK2/cyclinE, IC₅₀: 0.041 μM			Cdk5/p25, IC₅₀: 0.11 μM		CDK7/cyclin H, IC₅₀: 1.1 μM		CDK9/Cyclin T, IC₅₀: 0.18 μM										98.95%
Lerociclib dihydrochloride	CDK1/cyclinB1, IC₅₀: 2.4 μM	cdk2/cyclin A, IC₅₀: 1.5 μM CDK2/cyclinE, IC₅₀: 3.6 μM		Cdk4/cyclin D1, IC₅₀: 1 nM	CDK5/p35, IC₅₀: 832 nM Cdk5/p25, IC₅₀: 1.2 μM	cdk6/cyclin D3, IC₅₀: 2 nM	CDK7/Cyclin H/MAT1, IC₅₀: 2.4 μM		CDK9/Cyclin T, IC₅₀: 28 nM										98.11%
BS-181 hydrochloride	CDK1/cycB, IC₅₀: 8.1 μM	CDK2/Cyc E, IC₅₀: 0.88 μM		CDK4/Cyc D1, IC₅₀: 33 μM	CDK5/p35NCK, IC₅₀: 3 μM	CDK6/cycD1, IC₅₀: 47 μM	CDK7/CycH/MAT1, IC₅₀: 0.021 μM		CDK9/cycT, IC₅₀: 4.2 μM										99.80%
Trilaciclib hydrochloride				Cdk4/cyclin D1, IC₅₀: 1 nM		cdk6/cyclin D3, IC₅₀: 4 nM													99.69%
SU9516	CDK1, IC₅₀: 40 nM	CDK2, IC₅₀: 22 nM		CDK4, IC₅₀: 200 nM															99.81%
CDK5 inhibitor 20-223		CDK2, IC₅₀: 6.0 nM			CDK5, IC₅₀: 8.8 nM														99.78%
THZ2	CDK1, IC₅₀: 96.9 nM	CDK2, IC₅₀: 222 nM			CDK5, IC₅₀: 134 nM		CDK7, IC₅₀: 13.9 nM	CDK8, IC₅₀: 6830 nM	CDK9, IC₅₀: 194 nM										99.03%
BRD6989								CDK8, IC₅₀: ~200 nM recombinant CDK8, IC₅₀: ~0.5 μM							recombinant CDK19, IC₅₀: >30 μM				99.56%
Atuveciclib	CDK1/CycB(h), IC₅₀: 1100 nM	CDK2/CycE(h), IC₅₀: 1000 nM	CDK3/CycE(h), IC₅₀: 890 nM		CDK5/p35(h), IC₅₀: 1600 nM				CDK9/CycT1, IC₅₀: 13 nM CDK9/CycT1(h), IC₅₀: 6 nM										99.80%
JSH-150	Cdk1/cyclin B, IC₅₀: 1.34 μM	cdk2/cyclin A, IC₅₀: 2.86 μM			Cdk5/p25, IC₅₀: 4.64 μM		CDK7/Cyclin H/MNAT1, IC₅₀: 1.72 μM		CDK9/cyclinT1, IC₅₀: 1 nM				CDK14/Cyclin Y, IC₅₀: 1.68 μM	CDK16/Cyclin Y, IC₅₀: 292 nM					98.36%
CDK2-IN-4	Cdk1/cyclin B, IC₅₀: 86 μM	cdk2/cyclin A, IC₅₀: 44 nM
GFB-12811		CDK2/CycA, IC₅₀: 211 nM			Cdk5/p25, IC₅₀: 2.3 nM		CDK7/Cyclin H/MAT1, IC₅₀: 718 nM		CDK9/CycT1, IC₅₀: 894 nM										98.04%
Purvalanol B	cdc2/cyclin B, IC₅₀: 6 nM	cdk2/cyclin A, IC₅₀: 6 nM CDK2/cyclinE, IC₅₀: 9 nM			CDK5/p35, IC₅₀: 6 nM
CDK12-IN-3											CDK12, IC₅₀: 491 nM								99.86%
Narazaciclib				Cdk4/cyclin D1, IC₅₀: 3.9 nM		CDK6/cyclinD1, IC₅₀: 9.82 nM													99.12%
CDK12-IN-2		CDK2, IC₅₀: >100 μM					CDK7, IC₅₀: >10 μM CDK7, IC₅₀: >10 μM		CDK9, IC₅₀: 16 μM		CDK12, IC₅₀: 52 nM								99.36%
MC180295	CDK1-Cyclin B, IC₅₀: 138 nM	cdk2-cyclin A, IC₅₀: 233 nM cdk2-cyclin E, IC₅₀: 367 nM	CDK3-Cyclin E, IC₅₀: 399 nM	CDK4-Cyclin D, IC₅₀: 112 nM	cdk5-p35, IC₅₀: 159 nM cdk5-p25, IC₅₀: 186 nM	cdk6-cyclin D3, IC₅₀: 712 nM	CDK7-CycH/MAT1, IC₅₀: 555 nM		CDK9- Cyclin T1, IC₅₀: 5 nM										98.89%
PROTAC CDK9 Degrader-1									CDK9										98.03%
CP-10						CDK6, DC₅₀: 2.1 nM													98.22%
TC11	CDK1																		98.04%
PHA-793887	Cdk1/cyclin B, IC₅₀: 60 nM	cdk2/cyclin A, IC₅₀: 8 nM CDK2/cyclinE, IC₅₀: 8 nM		Cdk4/cyclin D1, IC₅₀: 62 nM	Cdk5/p25, IC₅₀: 5 nM		CDK7/cyclin H, IC₅₀: 10 nM		CDK9/cyclinT1, IC₅₀: 138 nM										99.25%
Thiabendazole	CCNE1	CDK2																	99.77%
LY2857785							CDK7, IC₅₀: 0.246 μM	CDK8, IC₅₀: 0.016 μM	CDK9, IC₅₀: 0.011 μM										99.92%
CKI-7 free base																Cdc7			99.80%
FN-1501		cdk2/cyclin A, IC₅₀: 2.47 nM		Cdk4/cyclin D1, IC₅₀: 0.85 nM		CDK6/cyclinD1, IC₅₀: 1.96 nM													99.08%
CDK12-IN-E9		cdk2/cyclin A, IC₅₀: 932 nM					CDK7/Cyclin H/MNAT1, IC₅₀: 1210 nM		CDK9/cyclinT1, IC₅₀: 23.9 nM										99.97%
CLK1-IN-1																	CLK1, IC₅₀: 2 nM		98.79%
KH-CB19																	CLK1, IC₅₀: 19.7 nM CLK3, IC₅₀: 530 nM		99.31%
Abemaciclib metabolite M18 hydrochloride				CDK4		CDK6													98.01%
SEL120-34A hydrochloride								CDK8/CycC, IC₅₀: 4.4 nM	CDK9/cycT, IC₅₀: 1070 nM						CDK19/CycC, IC₅₀: 10.4 nM				99.98%
RGB-286638	cyclin B1-CDK1, IC₅₀: 2 nM	cyclin E-CDK2, IC₅₀: 3 nM	cyclin E-CDK3, IC₅₀: 5 nM	cyclin D1-CDK4, IC₅₀: 4 nM	p35-CDK5, IC₅₀: 5 nM	cyclin D3-CDK6, IC₅₀: 55 nM	cyclin H-CDK7, IC₅₀: 44 nM		T1-CDK9, IC₅₀: 1 nM										99.70%
PROTAC CDK12/13 Degrader-1 TFA											CDK12, DC₅₀: 2.2 nM	CDK13, DC₅₀: 2.1 nM							98.37%
ML167			CDK3, IC₅₀: ＞10000 nM														CLK4, IC₅₀: 136 nM CLK1, IC₅₀: 1522 nM CLK2, IC₅₀: 1648 nM		98.62%
YX-2-107						CDK6, IC₅₀: 4.4 nM													99.79%
Voruciclib	CDK1/cycB, Ki: 5.4 nM CDK1/cyc A, Ki: 9.1 nM			CDK4/Cyc D1, Ki: 3.96 nM		CDK6/cycD1, Ki: 2.92 nM			CDK9/cyc T2, Ki: 0.626 nM CDK9/CycT1, Ki: 1.68 nM										99.77%
Abemaciclib metabolite M20				CDK4		CDK6
CDK9-IN-1									CDK9/CycT1, IC₅₀: 39 nM										98.52%
Dalpiciclib				CDK4, IC₅₀: 12.4 nM		CDK6, IC₅₀: 9.9 nM													99.40%
AZ5576									CDK9, : <5 nM										99.88%
HS-243																	CLK4, IC₅₀: 662 nM		99.88%
JH-XI-10-02								CDK8, IC₅₀: 159 nM											99.82%
Riviciclib hydrochloride	CDK1-Cyclin B, IC₅₀: 0.079 μM	cdk2-cyclin A, IC₅₀: 0.224 μM cdk2-cyclin E, IC₅₀: 2.500 μM		cdk4-cyclin D1, IC₅₀: 0.063 μM		cdk6-cyclin D3, IC₅₀: 0.396 μM			CDK9- Cyclin T1, IC₅₀: 0.020 μM CDK9-cyclin H, IC₅₀: 2.900 μM										98.89%
Bisindolylmaleimide X hydrochloride		CDK2, IC₅₀: 200 nM																	98.90%
Senexin B								CDK8, Kd: 140 nM							CDK19, Kd: 80 nM				99.72%
Dalpiciclib hydrochloride				CDK4, IC₅₀: 12.4 nM		CDK6, IC₅₀: 9.9 nM													98.22%
NU6102	Cdk1/cyclin B, IC₅₀: 9.5 nM	CDK2/cyclin A3, IC₅₀: 5.4 nM		CDK4, IC₅₀: 1.6 μM															99.23%
DS96432529								CDK8											99.58%
(-)-Enitociclib									CDK9										99.69%
XY028-133				CDK4		CDK6													98.62%
CDK5-IN-3		CDK2/CycA, IC₅₀: 18 nM			Cdk5/p25, IC₅₀: 0.6 nM														99.49%
β-catenin-IN-3				Cdk4/cyclin D1															98.03%
XL413																Cdc7, IC₅₀: 3.4 nM			99.76%
Palbociclib-d₈				Cdk4/cyclin D3, IC₅₀: 9 nM Cdk4/cyclin D1, IC₅₀: 11 nM		Cdk6/cyclin D2, IC₅₀: 16 nM													99.84%
CDK9-IN-2									CDK9, IC₅₀: 5 nM (H929 multiple myeloma cell line)										99.37%
CC-671																	CLK2, IC₅₀: 0.006 μM		99.06%
Samuraciclib hydrochloride dihydrate	CDK1, IC₅₀: 1.8 μM	CDK2, IC₅₀: 578 nM		CDK4, IC₅₀: 49 μM	CDK5, IC₅₀: 9.4 μM	CDK6, IC₅₀: 31 μM	CDK7, IC₅₀: 41 nM		CDK9, IC₅₀: 1.2 μM										99.08%
AMG 925	CDK1, IC₅₀: 1.9 μM	CDK2, IC₅₀: 375 nM		CDK4, IC₅₀: 3 nM		CDK6, IC₅₀: 8 nM													98.20%
EHT 5372																	CLK1, IC₅₀: 22.8 nM CLK2, IC₅₀: 88.8 nM CLK4, IC₅₀: 59.0 nM		98.12%
RSS0680	CDK1	CDK2		CDK4		CDK6								CDK16/Cyclin Y					98.03%
Alsterpaullone	Cdk1/cyclin B, IC₅₀: 35 nM	cdk2/cyclin A, IC₅₀: 15 nM CDK2/Cyc E, IC₅₀: 200 nM			CDK5/p35, IC₅₀: 40 nM														99.85%
Olomoucine		cdk2-cyclin A, IC₅₀: 7 μM cdk2-cyclin E, IC₅₀: 7 μM			cdk5-p35, IC₅₀: 25 μM														99.78%
LY3177833																Cdc7, IC₅₀: 3.3 nM			99.48%
YKL-5-124 TFA		CDK2, IC₅₀: 1300 nM					CDK7, IC₅₀: 53.5 nM CDK7/Mat1/CycH, IC₅₀: 9.7 nM		CDK9, IC₅₀: 3020 nM										99.44%
Garcinone C							CDK7												99.66%
JH-XVI-178								CDK8, IC₅₀: 1 nM							CDK19, IC₅₀: 2 nM				98.16%
CDK-IN-2									CDK9/cyclinT1, IC₅₀: 8 nM										98.97%
LDC4297							CDK7, IC₅₀: 0.13 nM												98.25%
K00546	Cdk1/cyclin B, IC₅₀: 0.6 nM	cdk2/cyclin A, IC₅₀: 0.5 nM															CLK1, IC₅₀: 8.9 nM CLK3, IC₅₀: 29.2 nM		98.08%
Casein Kinase inhibitor A86							CDK7, Kd: 0.31 nM		CDK9, Kd: 5.4 nM										99.26%
FIT-039									CDK9/cyclinT1, IC₅₀: 5.8 μM										99.56%
CDK2-IN-3		CDK2, IC₅₀: 60 nM
MeBIO	Cdk1/cyclin B, IC₅₀: 55 μM				Cdk5/p25, IC₅₀: >100 μM														≥98.0%
NU6140	CDK1-Cyclin B, IC₅₀: 6.6 μM	cdk2-cyclin A, IC₅₀: 0.41 μM		CDK4-Cyclin D, IC₅₀: 5.5 μM	cdk5-p25, IC₅₀: 15 μM		cdk7-cyclin H, IC₅₀: 3.9 μM												99.07%
AS2863619 free base								CDK8, IC₅₀: 0.61 nM							CDK19, IC₅₀: 4.28 nM				99.87%
DB0614						CDK6								CDK16/Cyclin Y					98.80%
CDK4/6-IN-2				CDK4, IC₅₀: 2.7 nM		CDK6, IC₅₀: 16 nM													99.82%
Cimpuciclib tosylate				CDK4, IC₅₀: 0.49 nM		CDK6, IC₅₀: 9.56 nM													99.16%
BSJ-01-175											CDK12	CDK13							99.45%
CK7		CDK2							CDK9										99.72%
LDC4297 hydrochloride							CDK7, IC₅₀: 0.13 nM												98.23%
Longdaysin							CDK7, IC₅₀: 29 μM												99.83%
BGG463		CDK2																	≥98.0%
CDK9-IN-8									CDK9, IC₅₀: 12 nM										99.65%
CDK9-IN-7				CDK4/cyclin D, IC₅₀: 148 nM		CDK6/cyclinD, IC₅₀: 145 nM			CDK9/cyclinT1, IC₅₀: 11 nM										98.05%
GW8510		CDK2			CDK5														99.64%
CDK9-IN-13	CDK1, IC₅₀: 0.14 μM	CDK2, IC₅₀: 0.72 μM					CDK7, IC₅₀: 0.40 μM		CDK9, IC₅₀: <3 nM		CDK12, IC₅₀: 0.055 μM								99.94%
Avotaciclib	CDK1																		99.72%
TP-1287									CDK9
Ipivivint		CDK2, EC₅₀: 1 nM	CDK3, EC₅₀: 7 nM																99.95%
Manzamine A hydrochloride					CDK5, IC₅₀: 1.5 μM														99.66%
RGB-286638 free base	cyclin B1-CDK1, IC₅₀: 2 nM	cyclin E-CDK2, IC₅₀: 3 nM	cyclin E-CDK3, IC₅₀: 5 nM	cyclin D1-CDK4, IC₅₀: 4 nM	p35-CDK5, IC₅₀: 5 nM	cyclin D3-CDK6, IC₅₀: 55 nM	cyclin H-CDK7, IC₅₀: 44 nM		T1-CDK9, IC₅₀: 1 nM										98.07%
NSC 625987				CDK4/D1, IC₅₀: 0.2 μM															98.58%
CDK4/6-IN-15		CDK2, IC₅₀: 3.335 μM		CDK4, IC₅₀: 3 nM		CDK6, IC₅₀: 0.279 μM
NU2058	CDK1, IC₅₀: 26 μM	CDK2, IC₅₀: 17 μM CDK2, Ki: 12 μM																	99.66%
CDK1-IN-2	CDK1, IC₅₀: 5.8 μM
CDK8-IN-11								CDK8, IC₅₀: 46 nM											98.20%
AT7519 Hydrochloride	Cdk1/cyclin B, IC₅₀: 210 nM	cdk2/cyclin A, IC₅₀: 47 nM		Cdk4/cyclin D1, IC₅₀: 100 nM	CDK5/p35, IC₅₀: 13 nM	cdk6/cyclin D3, IC₅₀: 170 nM	CDK7/Cyclin H/MAT1, IC₅₀: 2400 nM		CDK9/Cyclin T, IC₅₀: 10 nM										99.42%
NVP-LCQ195	Cdk1/cyclin B, IC₅₀: 2 nM	cdk2/cyclin A, IC₅₀: 2 nM CDK2/cyclinE, IC₅₀: 5 nM	CDK3/Cyclin E, IC₅₀: 42 nM		Cdk5/p25, IC₅₀: 1 nM CDK5/p35, IC₅₀: 1 nM	cdk6/cyclin D3, IC₅₀: 187 nM	CDK7/Cyclin H/MAT1, IC₅₀: 3564 nM		CDK9/cyclinT1, IC₅₀: 15 nM										98.81%
Atuveciclib Racemate									CDK9										98.48%
Avotaciclib trihydrochloride	CDK1																		99.75%
JSH-009									CDK9										99.21%
(E/Z)-Zotiraciclib citrate		CDK2																	98.06%
Senexin C								CDK8/CycC, IC₅₀: 3.6 nM CDK8/CycC, Kd: 1.4 nM							CDK19/CycC, Kd: 2.9 nM				98.82%
GSK-3 inhibitor 3		CDK2, IC₅₀: 0.22 μM			CDK5, IC₅₀: 1.3 μM														98.72%
CDK8-IN-13								CDK8, IC₅₀: 51.9 nM											99.14%
Ca2+ channel agonist 1		CDK2, EC₅₀: 3.34 μM																	99.71%
CA224		cdk2-cyclin A, IC₅₀: 521 μM		cdk4-cyclin D1, IC₅₀: 6.2 μM															99.94%
CDK8-IN-1								CDK8, IC₅₀: 3 nM											99.77%
LL-K8-22								CDK8, DC₅₀: 2.52 μM											99.76%
BI-1622										CDK11B									98.97%
CAN508	Cdk1/cyclin B, IC₅₀: 44 μM	CDK2/cyclinE, IC₅₀: 20 μM cdk2/cyclin A, IC₅₀: 69 μM		Cdk4/cyclin D1, IC₅₀: 13.5 μM			CDK7/cyclin H, IC₅₀: 26 μM		CDK9/cyclinT1, IC₅₀: 0.35 μM										99.59%
GW297361	yeast Cdk1, IC₅₀: 20 nM human CDK1, IC₅₀: 30 nM	human CDK2, IC₅₀: 1.9 nM		human CDK4, IC₅₀: 300 nM					human CDK9, IC₅₀: 10 nM									yeast Pho85, IC₅₀: 400 nM	98.13%
CDK9-IN-11									CDK9
ON-013100				Cdk4/cyclin D1															98.66%
THZ1-R							CDK7, IC₅₀: 146 nM												98.12%
NU6027	CDK1, Ki: 2.5 μM	CDK2, Ki: 1.3 μM																	99.04%
Desmethylglycitein	CDK1	CDK2																	98.98%
DB1113				CDK4						CDK11B									99.28%
ABC1183									CDK9- Cyclin T1, IC₅₀: 321 nM										99.19%
NecroIr1				CDK4															98.02%
Butyrolactone I	CDK1																		98.03%
CDK9 inhibitor HH1									CDK9										99.56%
Ribociclib succinate hydrate				CDK4, IC₅₀: 10 nM		CDK6, IC₅₀: 39 nM													99.96%
Samuraciclib hydrochloride hydrate	CDK1, IC₅₀: 1.8 μM	CDK2/cycE1, IC₅₀: 578 nM		CDK4, IC₅₀: 49 μM	CDK5, IC₅₀: 9.4 μM	CDK6, IC₅₀: 34 μM	CDK7/CycH/MAT1, IC₅₀: 41 nM		CDK9, IC₅₀: 1.2 μM										99.88%
CDK9-IN-10									CDK9										98.00%
CDK12-IN-5		CDK2/cyclinE, IC₅₀: 173 μM							CDK9/cyclinT1, IC₅₀: 127 μM		CDK12, IC₅₀: 23.9 nM								99.01%
CLK1-IN-3																	CLK1, IC₅₀: 5 nM CLK2, IC₅₀: 42 nM CLK4, IC₅₀: 108 nM		98.03%
(E/Z)-Zotiraciclib hydrochloride		CDK2																	99.90%
CDK8/19-IN-1								CDK8/CycC, IC₅₀: 0.46 nM	CDK9, IC₅₀: 270 nM						CDK19/CycC, IC₅₀: 0.99 nM				98.03%
CDDD11-8									CDK9, Ki: 8 nM										99.62%
Voruciclib hydrochloride	CDK1/cycB, Ki: 5.4 nM CDK1/cyc A, Ki: 9.1 nM			CDK4/Cyc D1, Ki: 3.96 nM		CDK6/cycD1, Ki: 2.92 nM			CDK9/CycT1, Ki: 1.68 nM CDK9/cyc T2, Ki: 0.626 nM										99.23%
KH-CB20																	CLK1, IC₅₀: 16.5 nM CLK3, IC₅₀: 488 nM		99.80%
PNU112455A hydrochloride		CDK2, Km: 3.6 μM			CDK5, Km: 3.2 μM														99.56%
PROTAC CDK12/13 Degrader-1											CDK12, DC₅₀: 2.2 nM	CDK13, DC₅₀: 2.1 nM							98.01%
HTH-01-091							CDK7, IC₅₀: 1230 nM												98.64%
CDK7-IN-21							CDK7
Vanicoside B			CDK3																99.82%
Cdk1/2 Inhibitor III	Cdk1/cyclin B, IC₅₀: 2.1 μM																		99.69%
CDK9-IN-12									CDK9/cyclinT1, IC₅₀: 5.41 nM										99.65%
5-Iodo-indirubin-3'-monoxime	Cdk1/cyclin B, IC₅₀: 25 nM				Cdk5/p25, IC₅₀: 20 nM														99.50%
7BIO					CDK5														99.20%
CDK1-IN-1	CDK1/cycB, IC₅₀: 161.2 nM																		99.33%
(R)-DRF053 dihydrochloride	CDK1/cyclinB1, IC₅₀: 220 nM				Cdk5/p25, IC₅₀: 80 nM														99.30%
(R)-(+)-O-Demethylbuchenavianine	CDK1, IC₅₀: 1.1 μM				CDK5, IC₅₀: 0.95 μM														98.67%
Lerociclib	CDK1/cyclinB1, IC₅₀: 2.4 μM	cdk2/cyclin A, IC₅₀: 1.5 μM CDK2/cyclinE, IC₅₀: 3.6 μM		Cdk4/cyclin D1, IC₅₀: 1 nM	CDK5/p35, IC₅₀: 0.832 μM Cdk5/p25, IC₅₀: 1.2 μM	cdk6/cyclin D3, IC₅₀: 2 nM	CDK7/Cyclin H/MAT1, IC₅₀: 2.4 μM		CDK9/Cyclin T, IC₅₀: 28 nM										98.35%
HEMTAC CDK4/6 degrader 1				CDK4		CDK6
Bohemine		CDK2/cyclinE, IC₅₀: 4.6 μM cdk2/cyclin A, IC₅₀: 83 μM							CDK9/cyclinT1, IC₅₀: 2.7 μM										98.93%
YKL-1-116							CDK7
CDK9-IN-14									CDK9, IC₅₀: 6.92 nM										99.91%
CDK7-IN-4							CDK7												98.87%
RGB-286147	CDK1/cyclinB, IC₅₀: 48 nM	CDK2/E, IC₅₀: 15 nM		CDK4/D1, IC₅₀: 839 nM		cdk6/cyclin D3, IC₅₀: 232 nM													98.60%
NSC693868	Cdk1/cyclin B, IC₅₀: 600 nM				Cdk5/p25, IC₅₀: 400 nM														≥99.0%
Ryuvidine				CDK4, IC₅₀: 6.0 μM															99.40%
NecroIr2				CDK4															98.99%
CGP-82996	CDK1/cyclinB, IC₅₀: >100 μM	CDK2/cyclinA, IC₅₀: >50 μM CDK2/cyclin E, IC₅₀: >50 μM		Cdk4/cyclin D1, IC₅₀: 1.5 μM CDK4/cyclin D2, IC₅₀: >50 μM	CDK5/p35, IC₅₀: 25 μM	CDK6/cyclinD1, IC₅₀: 5.6 μM Cdk6/cyclin D2, IC₅₀: >50 μM													98.12%
Lacto-N-fucopentaose I		CDK2/cyclinE																	≥98.0%
CDK7-IN-1							CDK7, IC₅₀: 100 nM												98.91%
(S)-LY3177833 hydrate																Cdc7
LY3177833 monhydrate																Cdc7, IC₅₀: 3.3 nM			99.76%
IV-361		CDK2, Ki: ≥1000 nM					CDK7, Ki: ≤50 nM												99.60%
BS-181	CDK1/cycB, IC₅₀: 8.1 μM	CDK2/Cyc E, IC₅₀: 0.88 μM		CDK4/Cyc D1, IC₅₀: 33 μM	CDK5/p35NCK, IC₅₀: 3 μM	CDK6/cycD1, IC₅₀: 47 μM	CDK7/CycH/MAT1, IC₅₀: 0.021 μM		CDK9/cycT, IC₅₀: 4.2 μM										98.10%
Akt1&PKA-IN-2		CDK2^a, IC₅₀: 0.69 μM
Manzamine A					CDK5, IC₅₀: 1.5 μM
JSH-009 dimaleate	CDK1/cyclinB, IC₅₀: 5410 nM	CDK2/cyclinA, IC₅₀: 6850 nM	CDK3/cyclin E1, IC₅₀: >10,000 nM		Cdk5/p25, IC₅₀: 6950 nM		CDK7/Cyclin H/MNAT1, IC₅₀: 3700 nM	CDK8/cyclin C, IC₅₀: >10,000 nM	CDK9/cyclinT1, IC₅₀: 0.928 nM	CDK11, IC₅₀: >10,000 nM			CDK14/Cyclin Y, IC₅₀: 2710 nM	CDK16/Cyclin Y, IC₅₀: 195 nM
Abemaciclib metabolite M18				CDK4		CDK6
KB-0742									CDK9/cyclinT1, IC₅₀: 6 nM										99.38%
CDK12-IN-6		CDK2/cyclinE, IC₅₀: >20 μM							CDK9/cyclinT1, IC₅₀: >20 μM		CDK12, IC₅₀: 1.19 μM								98.09%
BS-194	CDK1, IC₅₀: 30 nM	CDK2, IC₅₀: 3 nM			CDK5, IC₅₀: 30 nM		CDK7, IC₅₀: 250 nM		CDK9, IC₅₀: 90 nM										99.36%
(E/Z)-BIO-acetoxime	CDK1/cyclinB, IC₅₀: 63 μM	CDK2/cyclinA, IC₅₀: 4.3 μM			Cdk5/p25, IC₅₀: 2.4 μM
AMG 925 HCl	CDK1, IC₅₀: 1.9 μM	CDK2, IC₅₀: 375 nM		CDK4, IC₅₀: 3 nM		CDK6, IC₅₀: 8 nM
PROTAC CDK4/6 degrader 1				CDK4, DC₅₀: 10.5 nM		CDK6, DC₅₀: 2.5 nM													98.88%
SEL120-34A								CDK8/CycC, IC₅₀: 4.4 nM	CDK9/cycT, IC₅₀: 1070 nM						CDK19/CycC, IC₅₀: 10.4 nM
Abemaciclib metabolite M20-d₈				CDK4		CDK6
Akt1&PKA-IN-1		CDK2, IC₅₀: 9.8 μM
CLK1/2-IN-1																	CLK1, IC₅₀: 16 nM CLK2, IC₅₀: 45 nM		99.87%
AT7519 TFA	Cdk1/cyclin B, IC₅₀: 210 nM	cdk2/cyclin A, IC₅₀: 47 nM		Cdk4/cyclin D1, IC₅₀: 100 nM	CDK5/p35, IC₅₀: 13 nM	cdk6/cyclin D3, IC₅₀: 170 nM	CDK7/Cyclin H/MAT1, IC₅₀: 2400 nM		CDK9/Cyclin T, IC₅₀: 10 nM										98.53%
PHA-767491	CDK1, IC₅₀: 250 nM	CDK2, IC₅₀: 240 nM			CDK5, IC₅₀: 460 nM				CDK9, IC₅₀: 34 nM										99.85%
JA397													CDK14/Cyclin Y, EC₅₀: 27.1 nM	CDK16/Cyclin Y, EC₅₀: 39.0 nM
CDD-2807																	CLK4, IC₅₀: 85 nM CLK2, IC₅₀: 101 nM CLK1, IC₅₀: 116 nM
Palbociclib dihydrochloride				Cdk4/cyclin D3, IC₅₀: 9 nM Cdk4/cyclin D1, IC₅₀: 11 nM		Cdk6/cyclin D2, IC₅₀: 16 nM
Palbociclib orotate				Cdk4/cyclin D3, IC₅₀: 9 nM Cdk4/cyclin D1, IC₅₀: 11 nM		Cdk6/cyclin D2, IC₅₀: 16 nM
Cimpuciclib				CDK4, IC₅₀: 0.49 nM		CDK6, IC₅₀: 9.56 nM
CDK1-IN-5	CDK1, IC₅₀: 42.19 nM	CDK2, IC₅₀: 188.71 nM			CDK5, IC₅₀: 354.15 nM
Samuraciclib	CDK1, IC₅₀: 1.8 μM	CDK2/cycE1, IC₅₀: 578 nM		CDK4, IC₅₀: 49 μM	CDK5, IC₅₀: 9.4 μM	CDK6, IC₅₀: 34 μM	CDK7/CycH/MAT1, IC₅₀: 41 nM		CDK9, IC₅₀: 1.2 μM
YJ1206											CDK12	CDK13
ZLMT-12		CDK2, IC₅₀: 0.011 μM							CDK9, IC₅₀: 0.002 μM
CDK7-IN-2 hydrochloride hydrate							CDK7
CDK1-IN-3	CDK1, IC₅₀: 36.8 nM	CDK2, IC₅₀: 305.17 nM			CDK5, IC₅₀: 369.37 nM
CDK4/6-IN-3	CDK1, Ki: 110 nM			CDK4, Ki: 0.3 nM		CDK6, Ki: 2.2 nM
HDAC1/2 and CDK2-IN-1		CDK2, IC₅₀: 0.80 nM
CDK2-IN-22		CDK2, IC₅₀: 64.42 nM																	98.64%
FN-1501-propionic acid		CDK2							CDK9
OTS964										CDK11B, Kd: 40 nM
CDK6/9-IN-1						CDK6, IC₅₀: 40.5 nM			CDK9, IC₅₀: 39.5 nM
Amantadine sulfate		CDK2
CDK7-IN-11							CDK7, IC₅₀: 4.2 nM
BS-181 dihydrochloride		CDK2, IC₅₀: 880 nM			CDK5, IC₅₀: 3000 nM		CDK7, IC₅₀: 21 nM		CDK9, IC₅₀: 4200 nM
Senexin A hydrochloride								CDK8, IC₅₀: 280 nM CDK8, Kd: 0.83 μM							CDK19, Kd: 0.31 μM
CDK9-IN-9		CDK2, IC₅₀: 155 nM							CDK9, IC₅₀: 1.8 nM
ZLHQ-5f		CDK2/CycA2, IC₅₀: 0.145 μM
YJ9069											CDK12	CDK13
CDK7-IN-29							CDK7, IC₅₀: 1.4 nM
CDK8-IN-5								CDK8, IC₅₀: 72 nM
CDK4/6-IN-21 maleate				CDK4, IC₅₀: 3.88 nM		CDK6, IC₅₀: 3.31 nM
CDK-TCIP1									CDK9
Haspin-IN-2																	CLK1, IC₅₀: 445 nM
CDK2 degrader 3		CDK2
CDK2-IN-30		CDK2, IC₅₀: ≤ 20 nM
ZDLD13				CDK4/CycD3, IC₅₀: 0.38 μM
PROTAC FLT3/CDKs degrader-1		CDK2, DC₅₀: 18.73 nM
ALK-IN-29		CDK2
CDK7-IN-30	CDK1, IC₅₀: >10000.00 nM	CDK2, IC₅₀: 734.55 nM	CDK3, IC₅₀: 370.40 nM	CDK4, IC₅₀: 644.80 nM	CDK5, IC₅₀: 3678.50 nM	CDK6, IC₅₀: 1345.50 nM	CDK7, IC₅₀: 7.21 nM		CDK9, IC₅₀: 704.3 nM
CDK9-IN-22		cdk2/cyclin A, IC₅₀: 876.2 nM							CDK9/cyclinT1, IC₅₀: 10.4 nM
CDK7-IN-27		CDK2, IC₅₀: 19.4 nM					CDK7, IC₅₀: 3 nM
CDK4/6-IN-19				CDK4, IC₅₀: 0.2 nM		CDK6, IC₅₀: 5.0 nM
PSTAIR																CDC28
Antitumor agent-174	CDK1/cyclinB1
Ulecaciclib		cdk2/cyclin A, Ki: 0.62 μM		Cdk4/cyclin D1, Ki: 0.2 nM		cdk6/cyclin D3, Ki: 3 nM	cdk7-cyclin H, Ki: 0.63 μM
CDK2-IN-14-d₃		CDK2
CDK2/4-IN-1		CDK2		CDK4
CDK1-IN-4	CDK1, IC₅₀: 44.52 nM	CDK2, IC₅₀: 621.93 nM			CDK5, IC₅₀: 135.22 nM
CDK2-IN-28		CDK2, Ki: 1 nM ([1])			CDK5, Ki: 15.8 nM ([1])		CDK7, Ki: 54.7 nM ([1])		CDK9, Ki: 12.8 nM ([1])
PROTAC CDK9/CycT1 Degrader-2									CDK9, IC₅₀: 45 nM
CPD-10				CDK4
CDK19 Probe 1															CDK19, IC₅₀: 1.01 μM
CDK-IN-12				CDK4, IC₅₀: <20 nM		CDK6, IC₅₀: <20 nM
HDAC1/CDK7-IN-1							CDK7, IC₅₀: 893 nM
CDK12-IN-4		CDK2/cyclinE, IC₅₀: >20 μM							CDK9/cyclinT1, IC₅₀: >20 μM		CDK12, IC₅₀: 0.641 μM
SLM6									CDK9/cyclinT1, IC₅₀: 133 nM
P-gp/CDK2-IN-1		CDK2
Cdc7-IN-15																Cdc7
CDK9-IN-19									CDK9/cyclinT1, IC₅₀: 2 nM
Haspin-IN-1																	CLK1, IC₅₀: 221 nM
CDK8-IN-10								CDK8, IC₅₀: 8.25 nM
CDK2/4/6-IN-1		CDK2, IC₅₀: 2.5 nM		CDK4, IC₅₀: 23.7 nM		CDK6, IC₅₀: 44.3 nM
CDK9-IN-23									CDK9, IC₅₀: <20 nM
CDK7/9-IN-1							CDK7, IC₅₀: 5.74-65.6 nM		CDK9, IC₅₀: 2.14 μM
Anticancer agent 30		CDK2
PROTAC CDK9 degrader-6									CDK9₄₂, DC₅₀: 0.03 μM CDK9₅₅, DC₅₀: 0.05 μM
CDK1/Cyc B-IN-1	CDK1-Cyclin B, IC₅₀: 97 nM																		98.47%
CDK4/6-IN-7				CDK4, IC₅₀: 1.58 nM		CDK6, IC₅₀: 4.09 nM
CLZX-205									CDK9, IC₅₀: 2.9 nM
CDK4/6-IN-16				CDK4, IC₅₀: 13 nM
CDK2-IN-26		CDK2
CDK4/6-IN-10				CDK4, IC₅₀: 22 nM		CDK6/cyclinD1, IC₅₀: 10 nM
KDM1/CDK1-IN-1	CDK1, IC₅₀: 0.078 ± 2. μM
CDK7-IN-8							CDK7, IC₅₀: 54.29 nM
CDK7-IN-7							CDK7, IC₅₀: <50 nM
CDK6/PIM1-IN-1	CDK1/cyclinB, IC₅₀: >10 μM	CDK2/cyclinA, IC₅₀: 2.274 μM	CDK3/Cyclin E, IC₅₀: >10 μM	Cdk4/cyclin D1, IC₅₀: 3.6 nM	Cdk5/p25, IC₅₀: >10 μM	CDK6/cyclinD1, IC₅₀: 39 nM	CDK7/Cyclin H/MNAT1, IC₅₀: 393 nM		CDK9/cyclinT1, IC₅₀: 440 nM		CDK12/Cyclin K, IC₅₀: >10 μM	CDK13/Cyclin K, IC₅₀: >10 μM
CDK8-IN-6								CDK8, Kd: 13 nM
CDK9-IN-28									CDK9/cyclinT1
CDK4/6-IN-8				CDK4, IC₅₀: 5.01 nM		CDK6, IC₅₀: 3.97 nM
CDK7-IN-5							CDK7, IC₅₀: <100 nM
GSK-3 inhibitor 4		CDK2, IC₅₀: 0.47 μM			CDK5, IC₅₀: 0.68 μM
CDK4/6-IN-9						CDK6/cyclinD1, IC₅₀: 905 nM
PROTAC CDK9 degrader-5									CDK9₄₂, DC₅₀: 0.10 μM CDK9₅₅, DC₅₀: 0.14 μM
CDKI-83	CDK1/B, Ki: 72 nM	CDK2/E, Ki: 232 nM		CDK4/D, Ki: 290 nM			CDK7/H, Ki: 405 nM		CDK9/T1, Ki: 21 nM
CDK5-IN-4		CDK2, IC₅₀: 6.24 ± 2.8 μM			CDK5, IC₅₀: 9.8 ± 2.29 μM				CDK9, IC₅₀: 1.76 ± 0.3 μM
PROTAC CDK9 degrader-2									CDK9, IC₅₀: 17 μM (MCF-7 cells)
CDK4 degrader 1				CDK4
CDK2-IN-8		CDK2, IC₅₀: 1.74 μM
(S)-LY3177833																Cdc7
Cdc7-IN-19																Cdc7, IC₅₀: 1.49 nM
CDK8-IN-12								CDK8, Ki: 14 nM											99.74%
CPD-39				CDK4
CDK1/2/4-IN-1	CDK1, IC₅₀: 1.47	CDK2, IC₅₀: 0.78		CDK4, IC₅₀: 0.87
TMX-2172		CDK2, IC₅₀: 6.5 nM			CDK5, IC₅₀: 6.8 nM
SZ-015268							CDK7, IC₅₀: 23.56 nM
CDK2-IN-12		CDK2, IC₅₀: 11.6 μM							CDK9, IC₅₀: >12.5 μM
CP-07									CDK9
CDK7-IN-31							CDK7, Kd: 0.18 nM
CDK5-IN-1					CDK5														98.47%
SHP2/CDK4-IN-1				CDK4, IC₅₀: 18.2 ± 1.3 nM
CDK4/6-IN-20				CDK4, IC₅₀: 1.9 nM		CDK6, IC₅₀: 14.2 nM
Multi-kinase-IN-4		CDK2, IC₅₀: 2.09 μM
Cdc7-IN-12																Cdc7, IC₅₀: <1 nM
CDK-IN-14		CDK2/CycA2, IC₅₀: 0.097 μM
CDK8 ligand 1								CDK8
CDK2-IN-18		CDK2/cyclinE, IC₅₀: 8 nM		Cdk4/cyclin D1, IC₅₀: 46 nM
CDK4/6-IN-12				CDK4, IC₅₀: 592.3 nM		CDK6, IC₅₀: 3090 nM
EGFR-IN-45		CDK2, IC₅₀: 1.6 μM
CDK7-IN-20	CDK1, IC₅₀: 3375 nM	CDK2, IC₅₀: 823 nM	CDK3, IC₅₀: 1837 nM		CDK5, IC₅₀: >10,000 nM	CDK6, IC₅₀: 950 nM	CDK7, IC₅₀: 4 nM		CDK9, IC₅₀: 526 nM		CDK12, IC₅₀: >10,000 nM
ZDLD20				CDK4/CycD3, IC₅₀: 6.51 μM															99.84%
CDK9-IN-33		CDK2, IC₅₀: 316.30 nM		CDK4, IC₅₀: 1771.00 nM		CDK6, IC₅₀: >10000 nM	CDK7, IC₅₀: 160 nM		CDK9, IC₅₀: 17.44 nM
BSJ-5-63							CDK7		CDK9		CDK12
3-Methylthienyl-carbonyl-JNJ-7706621	CDK1/cyclinB, IC₅₀: 6.4 nM	CDK2/cyclinA, IC₅₀: 2 nM		CDK4, IC₅₀: 0.11 μM
CDK-IN-9		CDK2/E, IC₅₀: 4 nM			Cdk5/p25, IC₅₀: 39 nM				CDK9/T1, IC₅₀: 20 nM		CDK12/K, IC₅₀: 64 nM	CDK13/K, IC₅₀: 22 nM
Wogonin (Standard)								CDK8
ARN25499																Cdc42
CLK1/2-IN-3																	CLK1, IC₅₀: 1.1 nM CLK2, IC₅₀: 2.1 nM
CDK1-IN-6	CDK1
CDK2-IN-29		CDK2, IC₅₀: 96 nM		CDK4, IC₅₀: 360 nM
Carbonic anhydrase inhibitor 14		CDK2, IC₅₀: 20.3 μM
Cdc7-IN-14																Cdc7, IC₅₀: <1 nM
YY173				CDK4, IC₅₀: 7.7 nM		CDK6, IC₅₀: 88 nM
Multi-kinase-IN-6		CDK2, IC₅₀: 0.71 μM
FLT3/ITD-IN-4														CDK16/Cyclin Y, EC₅₀: 1768 nM
Anticancer agent 29	CDK1/cyclinB1, IC₅₀: 0.127 μM	CDK2/cyclinE, IC₅₀: 0.054 μM		CDK4, IC₅₀: 0.129 μM		CDK6, IC₅₀: 0.396 μM
CDK9-IN-24									CDK9
CDK2-IN-20		CDK2/cyclinE, IC₅₀: 0.219 μM
XL413 hydrochloride																Cdc7, IC₅₀: 3.4 nM
CDK2-IN-7		CDK2/cyclinE, IC₅₀: 50 nM
CDK8/19-IN-2								CDK8/CycC, IC₅₀: 2.08 nM							CDK19/CycC, IC₅₀: 2.49 nM
CKI-7																Cdc7
PT-262		CDK2																	99.21%
CDK7-IN-28		cdk2/cyclin A, IC₅₀: 6224 nM					CDK7/Cyclin H/MNAT1, IC₅₀: ＜5 nM					CDK13/Cyclin K, IC₅₀: 152 nM
Aloisine RP106	Cdk1/cyclin B, IC₅₀: 0.7 μM				Cdk5/p25, IC₅₀: 1.5 μM
ZLC491											CDK12	CDK13
Aloisine A	CDK1/cyclinB, IC₅₀: 0.15 μM	CDK2/cyclinA, IC₅₀: 0.12 μM CDK2/cyclinE, IC₅₀: 0.4 μM			CDK5/p35, IC₅₀: 0.16 μM
CDK7-IN-16							CDK7, IC₅₀: 1~10 nM
FLT3/CDK4-IN-1				CDK4, IC₅₀: 7 nM
BMI-1026	CDK1, IC₅₀: 2.3 nM
CDK12-IN-7		CDK2, IC₅₀: 196 nM									CDK12, IC₅₀: 42 nM
CDK2-IN-9		CDK2, IC₅₀: 0.63 μM
Cdc7-IN-13																Cdc7, IC₅₀: <1 nM
CDK4/6-IN-21				CDK4, IC₅₀: 3.88 nM		CDK6, IC₅₀: 3.31 nM
CDK2-IN-15		CDK2, IC₅₀: 2.9 μM
LDC3140							CDK7, IC₅₀: <5 nM
PROTAC CDK9 degrader-9									CDK9
SHR5428	CDK1, IC₅₀: >100 μM	CDK2, IC₅₀: 8.99 μM		CDK4, IC₅₀: 3.87 μM		CDK6, IC₅₀: 5.89 μM	CDK7, IC₅₀: 0.005 μM		CDK9, IC₅₀: 8.30 μM		CDK12, IC₅₀: 1.11 μM
VCC972839:01									CDK9, IC₅₀: 7 nM
CDK9-IN-32									CDK9
Cdc7-IN-18																Cdc7, IC₅₀: 1.29 nM
TMX-3013	CDK1, IC₅₀: 0.9 nM	CDK2, IC₅₀: <0.5 nM		CDK4, IC₅₀: 24.5 nM	CDK5, IC₅₀: 0.5 nM	CDK6, IC₅₀: 15.6 nM
CDK/HDAC-IN-2	CDK1, IC₅₀: 8.63 nM	CDK2, IC₅₀: 0.30 μM		CDK4, IC₅₀: >1000 nM		CDK6, IC₅₀: >1000 nM	CDK7, IC₅₀: >1000 nM
ZLWT-37		CDK2, IC₅₀: 0.054 μM							CDK9, IC₅₀: 0.002 μM
CDK4/6-IN-14	CDK1, IC₅₀: >10000 nM	CDK2, IC₅₀: 1045 nM		CDK4, IC₅₀: 10 nM		CDK6, IC₅₀: 16 nM	CDK7, IC₅₀: 2595 nM		CDK9, IC₅₀: 2664 nM
CLK1/4-IN-1																	CLK1, IC₅₀: 9.7 nM CLK4, IC₅₀: 6.6 nM
CDK7-IN-10							CDK7, IC₅₀: ＜100 nM
CDK5-IN-2		CDK2/CycA, IC₅₀: 23 nM			Cdk5/p25, IC₅₀: 0.2 nM
CDK7-IN-6							CDK7, IC₅₀: ≤100 nM
CDK8-IN-7								CDK8, Kd: 3.5 nM
CDK8-IN-15								CDK8, IC₅₀: 57 nM
CDK4/6-IN-18				CDK4		CDK6
CDK2/4/6-IN-2		CDK2		CDK4		CDK6
PROTAC CDK9 degrader-8									CDK9, IC₅₀: 0.01 μM
EF-4-177		CDK2/cyclinE, IC₅₀: 87 nM
CDK2-IN-31		CDK2
CDK9-IN-34									CDK9, IC₅₀: 0.25 μM
(S)-Roscovitine	CDK1, IC₅₀: ≤1 μM	CDK2, IC₅₀: ≤1 μM			CDK5, IC₅₀: ≤1 μM		CDK7, IC₅₀: ≤1 μM		CDK9, IC₅₀: ≤1 μM
JTK-101									CDK9/cyclinT1
MU1210																	CLK1, IC₅₀: 8 nM CLK2, IC₅₀: 20 nM CLK4, IC₅₀: 12 nM
Olomoucine II	Cdk1/cyclin B, IC₅₀: 7.6 μM	CDK2/cyclinE, IC₅₀: 0.1 μM		CDK4/cyclinD1, IC₅₀: 19.8 μM			CDK7/cyclin H, IC₅₀: 0.45 μM		CDK9/cycT, IC₅₀: 0.06 μM
2-Cyanoethylalsterpaullone	Cdk1/cyclin B, IC₅₀: 0.23 nM
CCT68127		CDK2					CDK7		CDK9
CDK2-IN-27	CDK1/cyclinB1, IC₅₀: >10-20 nM nM	CDK2/cyclin E1, IC₅₀: <10 nM
PNU-292137	CDK1/cyclinB, IC₅₀: 270 nM	CDK2/cyclinA, IC₅₀: 37 nM CDK2/cyclin E, IC₅₀: 92 nM		CDK4/cyclinD1, IC₅₀: >10000 nM	Cdk5/p25, IC₅₀: 114 nM
Riviciclib	CDK1-Cyclin B, IC₅₀: 0.079 μM	cdk2-cyclin A, IC₅₀: 0.224 μM cdk2-cyclin E, IC₅₀: 2.540 μM		cdk4-cyclin D1, IC₅₀: 0.063 μM		cdk6-cyclin D3, IC₅₀: 0.396 μM			CDK9- Cyclin T1, IC₅₀: 0.020 μM CDK9-cyclin H, IC₅₀: 2.900 μM
Indirubin-3'-monoxime-5-sulphonic acid	CDK1, IC₅₀: 5 nM				CDK5, IC₅₀: 7 nM
Indirubin-5-sulfonate	Cdk1/cyclin B, IC₅₀: 55 nM	cdk2/cyclin A, IC₅₀: 35 nM CDK2/cyclinE, IC₅₀: 150 nM		Cdk4/cyclin D1, IC₅₀: 300 nM	CDK5/p35, IC₅₀: 65 nM
IIIM-290		CDK2/A, IC₅₀: 90 nM							CDK9/T1, IC₅₀: 94 nM

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

CDK Inhibitors

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z